Navigation Links
Spectros Corporation Sales and Licensing Revenue Up 32% in 2010
Date:2/10/2011

PORTOLA VALLEY, Calif., Feb. 10, 2011 /PRNewswire/ -- Spectros Corporation announces that sales and licensing revenue rose 32% (year-over-year) in 2010. This is the third year in a row for double-digit revenue growth for Spectros since the current T-Stat product line was launched in 2008. Spectros released certain 2010 financial results to shareholders today.

"This is a sign of the significant and growing reliance of physicians, patients, and hospitals on state-of-the-art tissue oximetry and spectroscopy devices and disposable sensors," notes CFO John Bagnatori.

"Due to the wide range of applications the T-Stat VLS Tissue Oximetry system may be applied to, it has been important to focus on the markets that perform strongest and will provide the greatest longevity," states Elizabeth van Thillo, director of Marketing. "We are excited at the rate of which sales and marketing efforts are ramping up and showing returns. Overall, we anticipate seeing a strong 2011 with the increasing adoption of tissue oximetry."

Spectros T-Stat® VLS Tissue Oximter and Continuum® Tissue Oximeters are the only broadband tissue oximeters on the market in the U.S. and Europe. T-Stat® and Continuum® compete in the marketplace with INVOS® oximeters marketed by Covidien. An expanded array of sensors, including Continuum® cerebral sensors are currently in testing, pending FDA approval and release anticipated over the next year.

About Spectros

Spectros markets and licenses advanced molecular sensing and imaging devices that shed light on ischemia and cancer. The company's champion product, the T-Stat VLS Tissue Oximeter, is the first medical device FDA-approved as sensitive to ischemia, an insufficient supply of oxygen to tissue.  T-Stat is the only commercially available tissue oximeter that utilizes state-of-the-art multispectral visible light spectroscopy (VLS) technology.  The non-invasive T-Stat VLS system is used clinically to provide a continuous and real-time absolute value, utilizing 260 wavelengths, over the competing NIRS oximeter product lines that only use 2-4.

Spectros also develops molecular diagnostic tools for breast and prostate cancer, currently in phase I/II clinical trials supported by the National Cancer Institute.  Spectros is a venture-supported private concern and markets its products in the U.S. and internationally.

(Note:  Forward-looking statements are intended as a guide only, and do not constitute an offer for investment nor a guarantee of future events or returns.  Certain Spectros applications described above have not been reviewed and approved by the FDA, and are therefore labeled for investigational use only.  T-Stat and Continuum are trademarks of the Spectros Corporation. INVOS is a trademark of Somanetics and Covidien).

For further information, visit www.spectros.com.


'/>"/>
SOURCE Spectros
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Spectros White LED Patent Scope Affirmed In U.S. Patent Office Reexamination
2. Spectros Presents New Clinical Studies Using T-Stat VLS Tissue Oximeter at Anesthesiology 2010
3. ICAP Ocean Tomo Offers IP Portfolio of Near-Infrared Spectroscopy Technology
4. Spectros Presents at the Pediatric Academic Societies (PAS) National Conference 2010
5. Spectros Corp. Enters Into Optical Biotechnology Patent Sale Agreement With Philips Electronics N.V.
6. Bioimpedance Spectroscopy is More Accurate and Reliable Than Other Methods of Subclinical Assessment of Lymphedema in Breast Cancer Patients, According to Paper Published in Journal of Clinical Oncology
7. FDA Grants Market Clearance for the LipiScan(TM) Coronary Imaging System Developed by InfraReDx, Inc. - A Novel Spectroscopy System for the Identification of Lipid Core Containing Plaques of Interest in the Coronary Arteries
8. Luminex Corporation Reports Fourth Quarter and Full Year 2010 Results
9. Unilife Corporation to Announce Financial Results for Fiscal 2011 Second Quarter on Monday, February 14, 2011
10. China Medicine Corporation Receives Manufacturing License for rADTZ
11. Endo Pharmaceuticals and Orion Corporation Begin Novel R&D Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
(Date:6/23/2016)... -- Research and Markets has announced the ... (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, ... Global Forecast to 2021" report to their offering. ... pharmaceutical excipients market is projected to reach USD 8.1 ... the forecast period 2016 to 2021. ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Medical Market Analysis 2016 - Forecast to 2022" report ... The report contains up to date financial data derived from ... of major trends with potential impact on the market during ... market segmentation which comprises of sub markets, regional and country ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/26/2016)... ... 2016 , ... PawPaws brand pet supplements owned by Whole Health ... the health of felines. The formula is all-natural and is made from Chinese herbs ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia ...
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... ... , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize ... Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into ... Simply select a ProHand generator and drag it above media or text in the ...
Breaking Medicine News(10 mins):